Part II of a series on the use of Ivermectin to treat COVID-19 in India
Authored by Dr. Justus R. Hope, writer’s pseudonym, graduated summa cum laude from Wabash College where he was named a Lilly Scholar. He attended Baylor College of Medicine where he was awarded the M.D. degree. He completed a residency in Physical Medicine & Rehabilitation at The University of California Irvine Medical Center. He is board-certified and has taught at The University of California Davis Medical Center in the departments of Family Practice and Physical Medicine & Rehabilitation. He has practiced medicine for over 35 years and maintains a private practice in Northern California.
Delhi Obliterates COVID with Ivermectin
“In India — where the Delta variant was first identified and caused a huge outbreak — cases have plunged over the past two months. A similar drop may now be underway in Britain. There is no clear explanation for these declines.”
David Leonhardt of the New York Times wrote this on July 30, 2021.
https://www.nytimes.com/2021/07/30/briefing/coronavirus-delta-mysteries.html
TrialSite News in May reported on “Beyond the Roundup” their analysis.
TSN reported that the Delta variant outbreak exploded in the last week of March, primarily in migrant workers. A large percent of these workers, up to 50% of all Indian citizens, travel to Mumbai each year. However, during April, as the outbreak spread, many workers returned to their hometowns, and many resided in Uttar Pradesh, causing this area to explode with cases.
On April 22, the ICMR and the AAIMS groups added Ivermectin to the India National protocol, and following this, according to TSN, cases dropped exponentially.
“At the national level, the massive surge that overtook the country at the beginning of April slowed exponentially after the new COVID-19 protocol was introduced, which includes the use of Ivermectin and Budesonide.” See Mark 6:58
“Cases in Uttar Pradesh, hometown to many migrant workers who fled Mumbai, have been dropping since April 24, and deaths have dropped since April 30.”
The narrator stated on May 15, 2021, that “the media is resistant to report on this topic (Ivermectin).”
“An important subsequent topic of study would be to compare the transmission rates, disease progression rates, and death rates among population exposed to the current Ivermectin and Budesonide regimen versus Remdesivir and other courses of action for more granular insight into care strategies.”
Subsequently, this question was answered. A natural population experiment unfolded where the Indian state of Tamil Nadu outlawed Ivermectin in favor of Remdesivir while Delhi and Uttar Pradesh continued Ivermectin.
The enormous success of Delhi was reviewed by this author twice:
The contrast with Tamil Nadu was reviewed:
https://www.thedesertreview.com/opinion/letters_to_editor/tamil-nadu-leads-india-in-new-infections-denies-citizens-ivermectin/article_32634012-ba66-11eb-9211-ab378d521f9a.html
The Burgundy graph above reveals the numbers in Delhi after they included Ivermectin in the protocol. Delhi is a city with 30 million inhabitants and, as of August 11, saw 37 new cases and ZERO deaths. By contrast, Tamil Nadu, a city of 78 million, saw 1964 new cases and 28 new deaths.
Tamil Nadu shares their rejection of Ivermectin and choice to use Remdesivir in common with the United States.
As of August 10, the United States, with 331 million inhabitants, saw 161,990 new cases and 1,049 new deaths. Uttar Pradesh is a state in India of comparable population to the US. Uttar Pradesh contains 241 million people. On August 10, Uttar Pradesh saw only 19 new cases and ONE death, over 1,000 times lower than the US.
The evidence in favor of Ivermectin is massive and overwhelming, which includes W.H.O. scientists Drs. Tess Lawrie’s and Andrew Hill’s recent highly-regarded and peer-reviewed publications [for anyone who wishes to show scientific data to their doctors]:
https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab358/6316214
https://pubmed.ncbi.nlm.nih.gov/34145166/
Dr. Pierre Kory also published a review:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/
Dr. Peter McCullough similarly published via preprint yet another review and all of these strongly showed the drug to be safe and effective against COVID-19.
https://www.medrxiv.org/content/10.1101/2021.07.06.21259924v1
What should alarm any reader is that Dr. Tess Lawrie reports that Dr. Andrew Hill’s paper’s conclusion was changed by his sponsor, and Dr. Hill was given a gag order on speaking to the media.
https://www.amazon.com/Ivermectin-World-Justus-R-Hope/dp/1737415909
But the bottom line remains why India’s Ivermectin experience remains under a media blackout. Why does the New York Times, who should know better, say it is all a great mystery?
TSN offers an answer, “Despite the (Indian) government’s insistence on promoting Ivermectin and Budesonide, the media hasn’t shown interest in sharing this news. (Instead), the comments continue to promote Remdesivir as an effective drug, and the few media outlets that do refer to Ivermectin call it an unproven medicine or an outdated treatment. It is as if there are two different treatment realities, (one) on the ground and (one) in the local health systems. Millions of patients are now receiving Ivermectin, yet one would never know by the media topics.” See Mark 5:15.
“It’s almost as if there is a blackout on the topic.”
Allow me to offer an explanation. The cost of Remdesivir is $3,100 per dose, while the cost of Ivermectin is pennies.
https://www.thedesertreview.com/opinion/letters_to_editor/big-pharma-uses-big-tobaccos-strategy-to-defeat-ivermectin/article_fc17022e-9ba6-11eb-8c7b-633764c1bf9e.html
While the US FDA is against using Ivermectin for COVID-19 outside of a clinical trial, the NIH is neither for or against and leaves the choice up to individual doctors treating individual patients as a matter of choice.
If India’s Ivermectin-using states have 1/1000 of the deaths non-Ivermectin-using countries have, why would you not?